PL3927314T3 - Minimalizacja aglomeracji materiału powlekającego cząstki leku podczas przechowywania dla ustabilizowania czasów rozpadu produktów farmaceutycznych - Google Patents

Minimalizacja aglomeracji materiału powlekającego cząstki leku podczas przechowywania dla ustabilizowania czasów rozpadu produktów farmaceutycznych

Info

Publication number
PL3927314T3
PL3927314T3 PL20708585.3T PL20708585T PL3927314T3 PL 3927314 T3 PL3927314 T3 PL 3927314T3 PL 20708585 T PL20708585 T PL 20708585T PL 3927314 T3 PL3927314 T3 PL 3927314T3
Authority
PL
Poland
Prior art keywords
stabilize
coating material
during storage
material during
pharmaceutical products
Prior art date
Application number
PL20708585.3T
Other languages
English (en)
Inventor
Rosaleen MCLAUGHLIN
Simon Andrew Martyn HOWES
Craig WHEADON
Jonathon WHITEHOUSE
Original Assignee
Catalent U.K. Swindon Zydis Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent U.K. Swindon Zydis Limited filed Critical Catalent U.K. Swindon Zydis Limited
Publication of PL3927314T3 publication Critical patent/PL3927314T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20708585.3T 2019-02-22 2020-02-21 Minimalizacja aglomeracji materiału powlekającego cząstki leku podczas przechowywania dla ustabilizowania czasów rozpadu produktów farmaceutycznych PL3927314T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962809307P 2019-02-22 2019-02-22
PCT/GB2020/050423 WO2020169992A1 (en) 2019-02-22 2020-02-21 Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products

Publications (1)

Publication Number Publication Date
PL3927314T3 true PL3927314T3 (pl) 2024-02-19

Family

ID=69740395

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20708585.3T PL3927314T3 (pl) 2019-02-22 2020-02-21 Minimalizacja aglomeracji materiału powlekającego cząstki leku podczas przechowywania dla ustabilizowania czasów rozpadu produktów farmaceutycznych

Country Status (20)

Country Link
US (4) US11141380B2 (pl)
EP (2) EP3927314B1 (pl)
JP (2) JP7543291B2 (pl)
KR (1) KR20210130722A (pl)
CN (1) CN113453662A (pl)
AR (1) AR118419A1 (pl)
AU (1) AU2020225448B2 (pl)
BR (1) BR112021016485A2 (pl)
CA (1) CA3129434A1 (pl)
ES (1) ES2964108T3 (pl)
GB (2) GB2585413B (pl)
HU (1) HUE064287T2 (pl)
IL (1) IL285640A (pl)
MX (2) MX2021009845A (pl)
PH (1) PH12021552019A1 (pl)
PL (1) PL3927314T3 (pl)
SG (1) SG11202109022UA (pl)
TW (1) TW202045142A (pl)
WO (1) WO2020169992A1 (pl)
ZA (2) ZA202107030B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3129383A1 (en) 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Minimizing aeration of suspensions during in-line mixing
CN113490486B (zh) 2019-02-22 2025-10-17 康特伦英国斯温顿捷迪斯有限公司 最小化团聚、曝气和保持包含布洛芬的药物组合物的包衣
BR112021016485A2 (pt) * 2019-02-22 2021-10-13 Catalent U.K. Swindon Zydis Limited Minimização de aglomeração de material de revestimento de partícula de fármaco durante armazenamento para estabilizar tempos de desintegração de produtos farmacêuticos
AR118418A1 (es) 2019-02-22 2021-10-06 Catalent Uk Swindon Zydis Ltd Conservación de partículas ifa revestidas funcionalmente producidas mediante procesos de mezcla sin solvente en suspensión acuosa
MX2023001004A (es) 2020-07-31 2023-03-01 Catalent Uk Swindon Zydis Ltd Composiciones farmaceuticas que comprenden un ingrediente farmaceutico activo (api) recubierto.
LT4243797T (lt) 2020-11-16 2026-06-10 Orcosa Inc. Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB211423A (en) 1923-10-06 1924-02-21 Leopold Seeger Improved means for locking nuts
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
IT1183574B (it) 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
US5558880A (en) * 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
ES2202302T3 (es) 1991-05-28 2004-04-01 Mcneil-Ppc, Inc. Composicion masticable que libera un farmaco.
DE4119116C2 (de) 1991-06-10 1997-08-07 Boehme Chem Fab Kg Biologisch leicht eliminierbare Entschäumer für wäßrige Systeme
CA2128821A1 (en) 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
US5738875A (en) 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US6214386B1 (en) 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5976577A (en) 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
GB9814534D0 (en) 1998-07-03 1998-09-02 Courtaulds Coatings Holdings Powder coating compositions
FR2785539B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Particules enrobees d'ibuprofene cristallin granule
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
DE10003757A1 (de) 2000-01-28 2001-08-02 Knoll Ag Ibuprofen-Wirkstoffzubereitung
JP2002012557A (ja) 2000-06-28 2002-01-15 Lion Corp 内服薬組成物
JP5000835B2 (ja) 2000-08-25 2012-08-15 千寿製薬株式会社 水性懸濁液剤
IN192750B (pl) 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
JP2003055197A (ja) 2001-06-07 2003-02-26 Tanabe Seiyaku Co Ltd 機能性粒子含有口腔内速崩壊性製剤
CA2449731A1 (en) 2001-06-07 2002-12-19 Tanabe Seiyaku Co., Ltd. Functional grain-containing preparations quickly disintegrated in the oral cavity
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US20030185096A1 (en) 2002-11-26 2003-10-02 Hollstein Thomas E. Apparatus and methods for dispensing minute amounts of liquid
FR2850275B1 (fr) 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
US20040170686A1 (en) 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
US20040265373A1 (en) 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US20060024370A1 (en) 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
EP1621186A1 (en) * 2004-07-29 2006-02-01 Cephalon France Modafinil oral lyophilizate
DK1804764T3 (da) 2004-10-28 2008-09-29 Pantec Ag Fremstilling af et hurtigt henfaldende fast præparat ud fra et fast pulver og et frysetörringstrin
US20080096979A1 (en) 2004-11-08 2008-04-24 Rubicon Research Pvt. Ltd. Aqueous Pharmaceutical Coating
EP1843769A1 (en) 2005-01-07 2007-10-17 Pfizer Products Incorporated Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
WO2007074472A2 (en) 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
US20070148099A1 (en) 2005-12-27 2007-06-28 Burke Susan E Use of aroma compounds as defoaming agents for ophthalmic solutions with high concentrations of surfactants
CA2634232C (en) 2005-12-28 2013-08-20 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
US20070292508A1 (en) * 2006-06-05 2007-12-20 Balchem Corporation Orally disintegrating dosage forms
WO2008036299A2 (en) 2006-09-20 2008-03-27 Monosol Rx Llc Edible water-soluble film containing a foam reducing flavoring agent
MX2009004439A (es) * 2006-10-25 2009-05-11 Mcneil Ppc Inc Composicion de ibuprofeno.
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
ES2633928T3 (es) 2008-02-28 2017-09-26 R.P. Scherer Technologies, Llc Proceso para minimizar polimorfismo
TWI468191B (zh) 2009-01-28 2015-01-11 Novartis Ag 有機化合物之調配物
WO2011063531A1 (en) 2009-11-27 2011-06-03 Nuvo Research Inc. Topical ibuprofen formulations
US10548839B2 (en) 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
CN102579390A (zh) 2011-08-03 2012-07-18 天津市嵩锐医药科技有限公司 布洛芬定时释药三层片药物组合物及其制备方法
EP2741750A1 (en) 2011-08-12 2014-06-18 Dhanuka Laboratories Ltd. Pharmaceutical composition comprising cefuroxime
RU2476206C1 (ru) 2011-11-22 2013-02-27 Виктор Львович Лимонов Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)
WO2013183062A2 (en) * 2012-06-05 2013-12-12 Rubicon Research Private Limited Palatable formulations of ibuprofen
US9107851B2 (en) 2012-10-15 2015-08-18 New Jersey Institute Of Technology Solventless mixing process for coating pharmaceutical ingredients
ES2761407T3 (es) * 2013-03-15 2020-05-19 Aprecia Pharmaceuticals LLC Forma de dosificación rápidamente dispersable de topiramato
FR3027802B1 (fr) 2014-10-31 2018-03-02 Ethypharm Granules de principe actif a double masquage de gout, leur procede de preparation et comprimes orodispersibles les contenant
WO2017080566A1 (en) 2015-11-09 2017-05-18 Rontis Hellas S.A. Stable analgesic pharmaceutical composition and process for the preparation thereof
AR118418A1 (es) 2019-02-22 2021-10-06 Catalent Uk Swindon Zydis Ltd Conservación de partículas ifa revestidas funcionalmente producidas mediante procesos de mezcla sin solvente en suspensión acuosa
CN113490486B (zh) 2019-02-22 2025-10-17 康特伦英国斯温顿捷迪斯有限公司 最小化团聚、曝气和保持包含布洛芬的药物组合物的包衣
BR112021016485A2 (pt) 2019-02-22 2021-10-13 Catalent U.K. Swindon Zydis Limited Minimização de aglomeração de material de revestimento de partícula de fármaco durante armazenamento para estabilizar tempos de desintegração de produtos farmacêuticos
CA3129383A1 (en) 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Minimizing aeration of suspensions during in-line mixing

Also Published As

Publication number Publication date
SG11202109022UA (en) 2021-09-29
US20200268667A1 (en) 2020-08-27
WO2020169992A1 (en) 2020-08-27
MX2024000693A (es) 2024-02-07
GB2585413A (en) 2021-01-13
PH12021552019A1 (en) 2022-09-12
BR112021016485A2 (pt) 2021-10-13
US11026892B2 (en) 2021-06-08
CN113453662A (zh) 2021-09-28
AU2020225448B2 (en) 2025-09-18
IL285640A (en) 2021-09-30
US20210267899A1 (en) 2021-09-02
GB2585413B (en) 2023-04-26
KR20210130722A (ko) 2021-11-01
US12350372B2 (en) 2025-07-08
EP3927314B1 (en) 2023-08-23
EP4285897A2 (en) 2023-12-06
MX2021009845A (es) 2021-09-10
GB2597579A (en) 2022-02-02
ZA202202966B (en) 2024-02-28
JP2022521317A (ja) 2022-04-06
JP7543291B2 (ja) 2024-09-02
US11779540B2 (en) 2023-10-10
GB2597579A8 (en) 2022-03-02
US11141380B2 (en) 2021-10-12
EP3927314A1 (en) 2021-12-29
HUE064287T2 (hu) 2024-02-28
US20200390704A1 (en) 2020-12-17
AU2020225448A1 (en) 2021-10-14
AR118419A1 (es) 2021-10-06
US20230390205A1 (en) 2023-12-07
CA3129434A1 (en) 2020-08-27
GB202002479D0 (en) 2020-04-08
EP4285897A3 (en) 2024-02-21
JP7850207B2 (ja) 2026-04-22
ZA202107030B (en) 2022-07-27
GB202107177D0 (en) 2021-06-30
TW202045142A (zh) 2020-12-16
GB2597579B (en) 2023-04-26
ES2964108T3 (es) 2024-04-04
JP2024157034A (ja) 2024-11-06
EP3927314C0 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
ZA202107030B (en) Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
ZA201802706B (en) Compositions and methods of manufacturing protein microparticles
MY202371A (en) Hexone glucokinase inhibitor and use thereof
IL275220A (en) Oral administration of active drug substances
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
EP3633771A4 (en) PROCESS FOR MANUFACTURING GRAPH COATED POWDER MATERIAL AND PRODUCT OF THE PROCESS
NZ714517A (en) Delayed release cysteamine bead formulation
AU2015242791A1 (en) Drug Delivery Enhancer Comprising Substance For Activating Lysophospholipid Receptors
KR102462548B9 (ko) CD300c의 발현 억제제 또는 활성 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
EP3675941C0 (en) SINGLE DOSE DRY POWDER INHALER AND METHOD FOR SETTING UP A DRY POWDER SINGLE DOSE INHALER FOR DELIVERY OF A SPECIFIC DRUG
EA202090508A1 (ru) Изготовление фармацевтических составов
IL255120B (en) A pharmaceutical preparation containing 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one in the form of a spray-dried or miniaturized dispersion and its use for the treatment of cancer
WO2012053785A3 (ko) 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
SG11202112530VA (en) Pharmaceutical composition of a weak acid drug and methods of administration
IL304569A (en) A machine for preparing pharmaceutical products
JP2015120758A5 (pl)
EP3615011A4 (en) PHARMACEUTICAL COMPOSITION FOR IN VIVO ADMINISTRATION, PROCESS FOR THE PREPARATION OF A PHARMACOLOGICALLY ACTIVE PRINCIPLE SENSITIVELY INSOLUBLE IN WATER
IL304655A (en) Drying pharmaceutical powders
IL243368A0 (en) Pharmaceutical preparation against tuberculosis in the form of a coated tablet containing granules of rifapentine and isoniazid and a process for its preparation
IL281217A (en) Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
HUE066061T2 (hu) Hialuronsav és karnozin konjugátumát tartalmazó gyógyászati készítmények és alkalmazásuk
IL281398A (en) A process for preparing a pharmaceutical coated solid dosage form
PH12021550999A1 (en) Pharmaceutical composition comprising of remogliflozin or salt or ester thereof and vildagliptin or salt thereof
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
WO2016153262A3 (en) Pharmaceutical composition comprising the extract of platycodon grandiflorum enhanced effective saponin contents for treatment of rheumatoid arthritis